SENSEX NIFTY

Biosimilar

Apr 29, 2016 at 09:29 | Source: CNBC-TV18
Company will continue with tie-ups for biosimilar products. These will first be launched in India and then in other markets, says Satish Reddy, Chairman of Dr Reddys Lab.
Apr 27, 2016 at 11:59 | Source: CNBC-TV18
Biocon R&D team is working on the second phase of the development of oral insulin, and Kiran Mazumdar-Shaw, Chairman & MD, Biocon, hopes that it becomes an approved product in the next 2-3 years.
Apr 26, 2016 at 22:08 | Source: PTI
The Delhi High Court has allowed pharma firms, Biocon Ltd and Mylan Pharmaceuticals Pvt Ltd, to continue with manufacture and marketing of their breast cancer drug under their brand names 'CANMAb' and 'HERTRAZ'.
Apr 26, 2016 at 20:00 | Source: PTI
Biotechnology firm Biocon today said its product portfolio will not be affected by an order of the Delhi High Court that prevented the company from calling its breast cancer medicine Trastuzumab as a biosimilar of Roche's Herceptin.
Mar 28, 2016 at 16:04 | Source: CNBC-TV18
Getting approval to sell the biosimilar drug Glargine in Japan will open doors for the company, feels Kiran Mazumdar Shaw, Chairperson and Managing Director of Biocon.
Mar 28, 2016 at 15:28 | Source: Moneycontrol.com
"Ministry of Health, Labour and Welfare (MHLW) of Japan has approved its biosimilar insulin Glargine," says the company in its filing.
Mar 28, 2016 at 14:46 | Source: Moneycontrol.com
Ministry of Health, Labour and Welfare of Japan has approved Biocon's biosimilar Insulin Glargine.
Mar 11, 2016 at 15:16 | Source: PTI
These products will be registered and subsequently commercialised as a part of this agreement by TR-Pharm in Turkey," a company statement said here.
Mar 11, 2016 at 11:44 | Source: Moneycontrol.com
"Dr Reddy's and TR-Pharm entered into a strategic collaboration agreement for manufacture and commercialisation of a portfolio of biosimilar drugs in Turkey," the Hyderabad-based pharma company in its filing.
Mar 11, 2016 at 11:31 | Source: Moneycontrol.com
Dr Reddy's and TR-Pharm announced today a strategic collaboration agreement involving 3 biosimilar products.
Messages on Biosimilar »

stock specific

Platinum Member

219 Followers

Biocon  

USFDA to review Biocon-Mylan`s biosimilar drug for breast cancer news may give the push for the biocon share price to 1025 Read more at:

11.56 PM Jan 11th

N2O

Platinum Member

211 Followers

Biocon  

Hopefully Biocon-Mylan will get USFDA approval for biosimilars for breast cancer

9.17 PM Jan 11th

koppik

Gold Member

12 Followers

Biocon  

Gives visibility with goal date under the Biosimilar User Fee Act (BsUFA) of September 03, 2017!

7.47 PM Jan 11th

BSE/NSE Announcer

Platinum Member

20393 Followers

Biocon  

Biocon Ltd has informed BSE regarding a Press Release dated January 11, 2017, titled "U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocons Proposed Biosimilar Trastuzumab".

6.32 PM Jan 11th

savera_patn
a

Platinum Member

40 Followers

Biocon  

By December 2017 we will have 3 biosimilars approval and by July 2018 3 biosim in market.....let`s wait price action by July next year and thereafter!!!

11.31 AM Jan 10th

NIKHILN

Gold Member

19 Followers

Merck  

global growth. The regulatory environment is evolving fast on two major dimensions—intellectual property (IP) and affordability. The biosimilars [drugs similar to innovator biologic drugs] and generic drugs markets are already well-developed in India. We have competition for our biologic Gonal F

10.45 AM Jan 8th

dhruvfun

New Member

3 Followers

Biocon  

i can`t believe how people are not able to understand what biocon is !! biocon is a world class biopharma firm, that has world class talent pool of scientists!! its trastuzumab biosimilar is showing much better results than herceptin which generates 40,000 crores alone in revenue for roche!! it

10.07 AM Jan 5th

rjstocks99

New Member

0 Follower

Biocon  

Hope S. Rugo, professor of medicine at the University of California, San Francisco, said: This study was the last major step of a multiple-phased program to demonstrate that proposed biosimilar trastuzumab meets the criteria for equivalence in comparison to branded trastuzumab.

5.40 PM Dec 28th 2016

rjstocks99

New Member

0 Follower

Biocon  

The results confirm the efficacy, safety and immunogenicity of MYL-1401O, the proposed biosimilar trastuzumab co-developed by Mylan and Biocon, in comparison to branded trastuzumab, according to a company statement

5.33 PM Dec 28th 2016

rjstocks99

New Member

0 Follower

Biocon  

Biosimilar developed by Biocon, Mylan

5.30 PM Dec 28th 2016

News across the web »
Oct 19, 2016 at 02:15 | Source: FirstPost
Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.